Results 131 to 140 of about 138,725 (257)

Supplementary Tables 1-5 from Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAF^V600E Positive Thyroid Carcinoma

, 2023
Jessica Limberg, Caitlin E. Egan, Katherine D. Gray, Mandeep Singh, Zachary Loewenstein, Yanping Yang, Maria Cristina Riascos, Hala Al Asadi, Parima Safe, Steve El Eshaky, Heng Liang, Timothy M. Ullmann, Weibin Wang, Wei Li, Tuo Zhang, Jenny Xiang, Dessislava Stefanova, Moonsoo M. Jin, Rasa Zarnegar, Thomas J. Fahey, Irene M. Min   +20 more
openalex   +1 more source

Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis [PDF]

Qi Yao, Yixuan Zhu, Yanling Ma, Yanfang Pu, Xueting Yang, Zhiqing Zhang   +5 more
openalex   +1 more source

Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention

Open Access Rheumatology: Research and Reviews
Janet Pope,1 Axel Finckh,2 Lucia Silva-Fernández,3 Peter Mandl,4 Haiyun Fan,5 Jose L Rivas,6 Monica Valderrama,6 Maria Montoro6 1Division of Rheumatology, University of Western Ontario, London, Ontario, Canada; 2Division of Rheumatology, University ...
Pope J, Finckh A, Silva-Fernández L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M   +7 more
doaj  

The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells [PDF]

Georgios Kalampounias, Kalliopi Zafeiropoulou, Theodosia Androutsopoulou, Spyridon Alexis, Argiris Symeonidis, Panagiotis Katsoris   +5 more
openalex   +1 more source

JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

, 2021
Benjamin Klein, Regina Treudler, Jan C. Simon   +2 more
openalex   +1 more source

JAK Inhibitor INCB047986 [PDF]

, 2020
openaire   +1 more source

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications [PDF]

, 2023
Mark Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P. Cope, James Galloway   +12 more
openalex   +1 more source

Potential benefits of JAK inhibitor therapy in Blau syndrome: a case report. [PDF]

Front Immunol
Wang Y, Yu XJ, Zhang Z.
europepmc   +1 more source

Formononetin acts synergistically with a JAK2 inhibitor to suppress growth in myeloproliferative neoplasm by inhibiting JAK/STAT3 signaling pathway

, 2023
Huijun Jiang, Zaijing Fan, Jiashan Li, Xiaoqun Zheng   +3 more
openalex   +2 more sources

Identification of potential predictive biomarkers during JAK-inhibitor therapies in rheumatoid arthritis. [PDF]

Hum Genomics
Rózsa J, Csige D, Bodoki M, Hagymási-Szabó Z, Tóth F, Szamosi S, Horváth Á, Bodnár N, Végh E, Szántó S, Szűcs G, Pethő Z, Gyetkó Z, Bodoki L, Kádas J, Szekanecz Z, Póliska S.   +16 more
europepmc   +1 more source